An evaluation of rozanolixizumab-noli for the treatment of anti-AChR and anti-MuSK antibody-positive generalized myasthenia gravis

Volume 23, Issue 12, July - December 2023, Page 1163-1171 .

Source: Expert Opinion on Biological Therapy - December 28, 2023 Category: Drugs & Pharmacology Authors: Alexandria MaticNouf AlfaidiVera BrilThe Ellen & Martin Prosserman Centre for Neuromuscular Diseases, University Health Network, University of Toronto, Toronto, Ontario, Canada Source Type: research